

Preterm Premature Rupture Of Membranes between 34 and 37 weeks: EXpectant management versus Induction of Labour

Submission date 01/09/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 13/02/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/02/2015	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Christine Willekes

Contact details
P. Debijelaan 25
Maastricht
Netherlands
6202 AZ
+31 (0)43 387 4768
cwi@sgyn.azm.nl

Additional identifiers

Protocol serial number
5521

Study information

Scientific Title
Preterm Premature Rupture Of Membranes between 34 and 37 weeks: EXpectant management versus Induction of Labour

Acronym

PPROMEXIL

Study objectives

The aim of this study is to solve the dilemma for the obstetric gynaecologist regarding the optimal treatment of women with Preterm Premature Rupture Of the Membranes (PPROM) after 34 weeks of gestation. Therefore, we will compare the effectiveness of induction of labour after PPROM between 34 and 37 weeks gestation compared to expectant monitoring on neonatal infection. Also, cost effectiveness and quality of life is measured in both treatment arms and compared.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethical Committee of the University Hospital Maastricht, 03/03/2006, ref: MEC 05-240.5 /fh

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Premature rupture of the membranes

Interventions

Induction of labour versus expectant management

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Neonatal sepsis

Key secondary outcome(s)

1. Maternal morbidity (chorioamnionitis/sepsis)
2. Respiratory Distress Syndrome (RDS)
3. Neonatal disease
4. Instrumental delivery rate
5. Quality of life and costs

Completion date

01/01/2010

Eligibility

Key inclusion criteria

Pregnant women with PPRM at a gestational age from 34 + 0/7 until 37 weeks who have given informed consent.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Foetal distress
2. Major foetal anomalies
3. Meconium stained amniotic fluid
4. Maternal infection at entry
5. Monochorionic Diamniotic (MCDA) multiple pregnancy
6. Multiple pregnancy, first child breech presentation
7. Previous caesarean section
8. Diabetes mellitus (defined as use of insulin)
9. Renal disease (including Systemic Lupus Erythematosus [SLE])
10. Seropositive for Human Immunodeficiency Virus (HIV)
11. Haemolysis, Elevated Liver, Low Platelet (HELLP)/severe pre-eclampsia
12. Oliguria less than 500 ml/24 hours

Date of first enrolment

01/01/2007

Date of final enrolment

01/01/2010

Locations

Countries of recruitment

Netherlands

Study participating centre

P. Debijelaan 25

Maastricht

Netherlands
6202 AZ

Sponsor information

Organisation

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

ROR

<https://ror.org/01yaj9a77>

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2012		Yes	No
Results article	economic analysis results	01/04/2014		Yes	No
Protocol article	protocol	06/07/2007		Yes	No
Other publications	secondary analysis	01/09/2014		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes